About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.

A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Clinicaltrials.gov identifier NCT04064060

Recruitment Status Recruiting

First Posted August 21, 2019

Last update posted August 31, 2020

Study Description

Brief summary:

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects: - Subjects receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit in the opinion of the investigator from continuing treatment with luspatercept. - Placebo arm subjects from parent protocol (at the time of unblinding or in follow-up) crossing over to luspatercept treatment (provided subjects have met all requirements for entering the rollover study as per the parent protocol). - Subjects in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met (unless they meet requirements as per parent protocol to cross-over to luspatercept treatment). The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Subjects will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase. - Transition Phase (Screening): up to 21 days prior to enrollment - Treatment Phase: For subjects in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. For placebo arm subjects from parent protocol (at the time of unblinding or in follow-up) crossing over to luspatercept treatment (provided subjects have met all requirements for entering the rollover study as per the parent protocol) will start at a luspatercept dose of 1.0 mg/kg every 3 weeks (Q3W). This does not apply to subjects that are in long-term follow-up from the parent protocol. - Follow-up Phase: - 42 Day Safety Follow-up Phase: subjects will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting. - Long-term Post-treatment Follow-up (LTPTFU) Phase: All subjects who are continuing in the LTPTFU Phase, will continue to be followed for 5 years from Dose 1 of the parent protocol, or 3 years of post-treatment from last dose of the parent protocol, whichever occurs later. Subjects will be followed every 6 months until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Subjects will also be monitored for progression to AML or any malignancies/pre- malignancies. New anticancer or disease related therapies should be collected at the same time schedule. Subjects transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study. The rollover study will be terminated, and relevant subjects will discontinue from the study when all subjects fulfill 5 years from Dose 1 of the parent protocol, or 3 years of post-treatment from last dose of the parent protocol, whichever occurs later. The shift to commercial drug is an alternative way to stop the study.

  • Condition or Disease:Beta-thalassemia
    Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
    Myelodysplastic Syndromes (MDS)
  • Intervention/Treatment: Drug: Luspatercept
  • Phase: Phase 3
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 665 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 3b, Open Label, Single-arm Rollover Study to Evaluate Long Term Safety in Subjects Who Have Participated in Other Luspatercept (Ace-536) Clinical Trials.
  • Actual Study Start Date: August 2019
  • Estimated Primary Completion Date: March 2030
  • Estimated Study Completion Date: March 2030
Arms and interventions
Arm Intervention/treatment
Experimental: ACE-536
Luspatercept will be administered as a subcutaneous (SC) injection to subjects by the study staff at the clinical site and administration will be documented in the subject's source record.
Drug: Luspatercept
Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
Outcome Measures
  • Primary Outcome Measures: 1. Adverse Events (AEs) [ Time Frame: From enrollment until at least 42 Day Safety Follow-up Phase or EOS (Approximately 5 years). ]
    Type, frequency, severity of AEs, relationship of treatment emergent adverse events to luspatercept
  • 2. Number of subjects progressing to high/very high risk MDS or AML. [ Time Frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years) ]
    Progression to high/very high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (MDS and myelofibrosis [MF] only).
  • 3. Percentage of subjects progressing to high/very high risk MDS or AML [ Time Frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years) ]
    Progression to high/very high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (MDS and myelofibrosis [MF] only)
  • 4. Number of subjects developing other malignancies/pre-malignancies [ Time Frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years) ]
    Development of other malignancies/pre-malignancies
  • 5. Percentage of subjects developing other malignancies/pre-malignancies [ Time Frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years) ]
    Development of other malignancies/pre-malignancies
  • Secondary Outcome Measures: 1. Overall Survival [ Time Frame: Enrollment to Long-term post-treatment follow-up (Approximately, 5 years) ]
    Time from date of randomization until death from any cause
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

Subjects must meet all the following criteria to be enrolled in this study:

1. Subject is ≥ 18 years at the time of signing the informed consent form (ICF).

2. Subject is willing and able to adhere to the study visit schedule and other protocol
requirements.

3. Subject has been participating in a luspatercept trial and continues to fulfill all
the requirements of the parent protocol and the subject has been either:

1. Assigned to luspatercept treatment, continues to receive clinical benefit in the
opinion of the investigator and should continue to receive luspatercept
treatment, OR

2. Assigned to placebo arm in the parent protocol (at the time of unblinding or in
follow-up) and should cross over to luspatercept treatment, OR

3. Assigned to the Follow-up Phase of the parent protocol, previously treated with
luspatercept or placebo in the parent protocol who shall continue into Long-term
Post-treatment Follow-up Phase in the rollover study until the follow-up
commitments are met (unless requirements are met as per parent protocol to
crossover to luspatercept treatment).

4. Subject understands and voluntarily signs an informed consent document prior to any
study-related assessments or procedures being conducted.

5. Subject demonstrates compliance, as assessed by the investigator, with the parent
study protocol requirements.

6. Applies to on treatment subjects only- females of childbearing potential (FCBP)
defined as a sexually mature woman who:

1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral
oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer
therapy does not rule out childbearing potential) for at least 24 consecutive months (ie,
has had menses at any time in the preceding 24 consecutive months) and must:

1. Have two negative pregnancy tests as verified by the investigator prior to starting
study therapy. She must agree to ongoing pregnancy testing during the course of the
study, and after end of study therapy. This applies even if the subject practices true
abstinence* from heterosexual contact.

2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on
a monthly basis and source documented) or agree to use, and be able to comply with
highly effective, contraception without interruption, 35 days prior to starting
investigational product (IP), during the study therapy (including dose interruptions),
and for 84 days after discontinuation of study therapy.

7. Applies to on treatment subjects only- Male subjects must:

a. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a
condom during sexual contact with a pregnant female or a female of childbearing potential
while participating in the study, during dose interruptions and for at least 84 days
following investigational product discontinuation even if he has undergone a successful
vasectomy.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Applies to on treatment subjects only- Concomitant use of any medications/procedures
that are prohibited in the parent luspatercept protocol.

2. Subject has met one or more criteria for study discontinuation as stipulated in the
parent luspatercept protocol.

3. First luspatercept transition visit into rollover study > 21 days after end of study
(EOS) visit (last dose/visit in case of no EOS visit) of the parent luspatercept study
with the exception of those subjects already in the Post-treatment Follow up Phase
from the parent study. Note-Subject with current dose delays from the parent protocol
during the Transition Phase, will continue in the rollover protocol regardless of the
delay.

4. Applies to on treatment subjects only- Pregnant or breastfeeding females.

5. Subject has any significant medical condition, laboratory abnormality, psychiatric
illness, or is considered vulnerable by local regulations (eg, imprisoned or
institutionalized) that would prevent the subject from participating in the study.

6. Subject has any condition including the presence of laboratory abnormalities, which
places the subject at unacceptable risk if he/she were to participate in the study.

7. Subject has any condition that confounds the ability to interpret data from the study.

Contacts and Locations
Contacts

Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
Show 123 Study Locations
Sponsors and Collaborators

Celgene

Investigators

Study Director: Rodrigo Ito, M.D. Celgene Corporation

More Information
  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT04064060 History of Changes
  • Other Study ID Numbers: ACE-536-LTFU-001, U1111-1235-8123, 2018-002915-93
  • First Posted: August 21, 2019 Key Record Dates
  • Last Update Posted: August 31, 2020
  • Last Verified: August 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Yes
  • Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
  • Time Frame: See Plan Description
  • Access Criteria: See Plan Description
  • URL: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: ACE-536
    Luspatercept
    MDS
    Beta-thalassemia
    Myeloproliferative neoplasm (MPN)-associated myelofibrosis
  • Additional relevant MeSH terms: Preleukemia
    Myelodysplastic Syndromes
    Primary Myelofibrosis
    Thalassemia
    Myeloproliferative Disorders
    beta-Thalassemia